Back to top

Can-Fite BioPharma enrolls 247 patients in Piclidenoson trial

Can-Fite BioPharma (CANF) announced completion of enrolment of the first 247 patients in its Phase 3 study evaluating Piclidenoson for the treatmen...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Can-Fite Biopharma Ltd (CANF)